This year in the United States, nearly 200 states, nearly 221,000 men will be told they have prostate cancer. About 30 percent of those cancers will have already spread outside the prostate. Now doctors are working on a way to keep it from spreading even further.
Robert Miller is a force in front of his congregation. Preaching is his life's work.
"You gotta know Jesus," said Miller. "Though I walk through the valley."
His life's battle started 11 years ago when he as diagnosed with prostate cancer.
"All I heard was the word cancer and I'm thinking cancer, death," Miller said.
PSA levels the markers for prostate cancer ware considered high at four. At diagnosis, Miller's levels were nearly 80. His prostate was removed, but the cancer stayed behind.
Miller soon found Dr. Michael Carducci.
"When prostate cancer spreads, it first goes to the bones," said Dr. Carducci, Oncologist.
Dr. Carducci is studying the drug atrasentan to keep the cancer from getting there.
"This may not necessarily kill cancer cells per se, it may slow prostate cancer down to a trickle," Carducci said.
It does that by targeting endothelin, a protein overproduced in men with prostate cancer that has spread.
"We get to the lock before endothelin does and therefore, the cancer cells never see this growth factor, this protein that really stimulates further growth," Dr. Carducci said.
Studies show there was a 52 percent delay in the time it took for the cancer to progress. Miller still has cancer, but it hasn't reached his bones.
"Eleven years ago I never thought I would see 59. I am satisfied that God allowed me to live this long," said Miller.
There are three separate studies on this drug for prostate cancer currently ongoing.